XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue (Disaggregation of Revenue by Product) (Details) - USD ($)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Disaggregation of Revenue [Line Items]    
Revenue $ 6,960,000,000 $ 7,810,000,000
U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 4,436,200,000 5,174,600,000
Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 2,523,900,000 2,635,400,000
Diabetes    
Disaggregation of Revenue [Line Items]    
Revenue 4,190,400,000 3,388,200,000
Diabetes | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 3,075,000,000 2,276,600,000
Diabetes | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,115,400,000 1,111,600,000
Trulicity®    
Disaggregation of Revenue [Line Items]    
Revenue 1,977,100,000 1,741,300,000
Trulicity® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,547,400,000 1,313,900,000
Trulicity® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 429,700,000 427,400,000
Jardiance    
Disaggregation of Revenue [Line Items]    
Revenue 577,500,000 419,400,000
Jardiance | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 329,400,000 229,800,000
Jardiance | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 248,100,000 189,700,000
Mounjaro®    
Disaggregation of Revenue [Line Items]    
Revenue 568,500,000 0
Mounjaro® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 536,400,000 0
Mounjaro® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 32,000,000.0 0
Humalog®    
Disaggregation of Revenue [Line Items]    
Revenue 460,900,000 618,200,000
Humalog® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 271,600,000 368,900,000
Humalog® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 189,300,000 249,300,000
Humulin®    
Disaggregation of Revenue [Line Items]    
Revenue 252,000,000.0 273,200,000
Humulin® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 198,800,000 190,400,000
Humulin® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 53,200,000 82,800,000
Basaglar®    
Disaggregation of Revenue [Line Items]    
Revenue 209,300,000 191,500,000
Basaglar® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 135,400,000 119,300,000
Basaglar® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 73,900,000 72,200,000
Other diabetes    
Disaggregation of Revenue [Line Items]    
Revenue 145,100,000 144,600,000
Other diabetes | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 56,000,000.0 54,300,000
Other diabetes | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 89,200,000 90,200,000
Oncology    
Disaggregation of Revenue [Line Items]    
Revenue 1,356,000,000 1,353,000,000
Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 753,400,000 783,700,000
Oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 602,600,000 569,200,000
Verzenio®    
Disaggregation of Revenue [Line Items]    
Revenue 750,900,000 469,400,000
Verzenio® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 461,100,000 301,500,000
Verzenio® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 289,800,000 167,900,000
Cyramza®    
Disaggregation of Revenue [Line Items]    
Revenue 236,800,000 230,300,000
Cyramza® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 100,600,000 79,200,000
Cyramza® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 136,100,000 151,100,000
Erbitux®    
Disaggregation of Revenue [Line Items]    
Revenue 129,900,000 122,700,000
Erbitux® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 118,800,000 109,700,000
Erbitux® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 11,100,000 13,000,000.0
Alimta®    
Disaggregation of Revenue [Line Items]    
Revenue 58,200,000 343,900,000
Alimta® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 20,100,000 254,300,000
Alimta® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 38,100,000 89,700,000
Other oncology    
Disaggregation of Revenue [Line Items]    
Revenue 180,200,000 186,700,000
Other oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 52,800,000 39,000,000.0
Other oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 127,500,000 147,500,000
Immunology    
Disaggregation of Revenue [Line Items]    
Revenue 777,800,000 748,100,000
Immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 354,500,000 378,500,000
Immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 423,300,000 369,600,000
Taltz®    
Disaggregation of Revenue [Line Items]    
Revenue 527,000,000.0 488,100,000
Taltz® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 312,200,000 307,200,000
Taltz® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 214,800,000 180,800,000
Olumiant®    
Disaggregation of Revenue [Line Items]    
Revenue 228,900,000 255,600,000
Olumiant® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 42,300,000 71,300,000
Olumiant® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 186,500,000 184,300,000
Other immunology    
Disaggregation of Revenue [Line Items]    
Revenue 22,000,000.0 4,500,000
Other immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 0 0
Other immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 22,000,000.0 4,500,000
Neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 360,500,000 397,700,000
Neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 144,500,000 153,400,000
Neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 216,000,000.0 244,400,000
Emgality®    
Disaggregation of Revenue [Line Items]    
Revenue 154,300,000 149,300,000
Emgality® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 108,700,000 108,300,000
Emgality® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 45,600,000 41,000,000.0
Other neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 206,200,000 248,400,000
Other neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 35,800,000 45,100,000
Other neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 170,400,000 203,400,000
Other    
Disaggregation of Revenue [Line Items]    
Revenue 275,300,000 1,923,000,000
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 108,700,000 1,582,400,000
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 166,600,000 340,600,000
Forteo®    
Disaggregation of Revenue [Line Items]    
Revenue 122,300,000 137,400,000
Forteo® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 70,700,000 70,200,000
Forteo® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 51,700,000 67,300,000
Cialis®    
Disaggregation of Revenue [Line Items]    
Revenue 100,300,000 217,700,000
Cialis® | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 7,600,000 6,900,000
Cialis® | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 92,700,000 210,800,000
COVID-19 antibodies    
Disaggregation of Revenue [Line Items]    
Revenue 0 1,469,800,000
COVID-19 antibodies | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 0 1,455,200,000
COVID-19 antibodies | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 0 14,700,000
Other    
Disaggregation of Revenue [Line Items]    
Revenue 52,800,000 98,100,000
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 30,500,000 50,100,000
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue $ 22,200,000 $ 47,800,000